A randomized, placebo-controlled, multicenter study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in patients with pdvanced lung cancer

Gao, Y, Dai, X, Chen, G, YE, J and Zhou, S 2003, 'A randomized, placebo-controlled, multicenter study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in patients with pdvanced lung cancer', International Journal of Medicinal Mushrooms, vol. 5, no. 4, pp. 383-395.


Document type: Journal Article
Collection: Journal Articles

Title A randomized, placebo-controlled, multicenter study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in patients with pdvanced lung cancer
Author(s) Gao, Y
Dai, X
Chen, G
YE, J
Zhou, S
Year 2003
Journal name International Journal of Medicinal Mushrooms
Volume number 5
Issue number 4
Start page 383
End page 395
Total pages 13
Publisher Begell House Inc.
Abstract Preclinical studies have established that the polysaccharide fractions of Ganoderma lucidum (Ling Zhi, reishi mashroom) have potential antitumor activity. Recent clinical studies have demonstrated that G. lucidum polysaccharides enhanced host immune functions (e.g., enhanced natural killer cell activity) in patients with advanced solid tumor, although objective response was not observed. A randomized double-blind, placebo-controlled, multicenter clinical trial was conducted to evaluate the efficacy and safety of the G. lucidum polysaccharides, Ganopoly®, in patients with advanced lung cancer. Sixty-eight patients with histologically confirmed advanced lung cancer were enrolled. Eligibility criteria included con. rmation of diagnosis, objective measurable disease, a Karnofsky performance score і60, life expectancy of 12 weeks or greater, no recent or concomitant anticancer therapy, and informed consent. Patients were evaluated with respect to their extent of disease and quality of life (Karnofsky score), and hematologic and selected immunological and biochemical studies at baseline and after 12 weeks of treatment with oral Ganopoly or placebo at 600 mg three times daily. Patients in both groups were similar with respect to age, sex, treatment history, and lung tumor histology.
Subject Complementary and Alternative Medicine not elsewhere classified
DOI - identifier 10.1615/InterJMedicMush.v5.i4.40
Copyright notice © 2003 Begell House Inc.
ISSN 1521-9437
Versions
Version Filter Type
Altmetric details:
Access Statistics: 519 Abstract Views  -  Detailed Statistics
Created: Tue, 19 Feb 2013, 13:10:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us